




Overview on Recent COVID-19 Vaccine Updates

January 27, 2022

Housekeeping

- **How to Ask Questions**

- Click on the  icon found at the bottom part of your screen
- A box will open where you can type in questions, comments, indicate sound problems, etc.
- Use this throughout the webinar to ask questions

- **Slides & Recording**

- This webinar is being recorded and a link as well as slides will be emailed out through our listserv as well as posted on our website at: www.michigan.gov/COVIDvaccineprovider

Topics Covered

Booster Dose Updates

Additional Dose 5-11

Fully Vaccinated vs. Up to Date

EUA Fact Sheets

Interim Clinical Considerations


Pfizer Gray Cap

Moderna Label Changes

Fact Check

Resources

Booster Dose Updates



COVID-19 Vaccine Booster Dose Updates

Booster updates since our last Noontime Knowledge:

- Preference for mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) in most situations for the primary and booster vaccination
- Shortened booster dose interval for Pfizer & Moderna to 5 months
- Expanded booster dose recommendations to 12 through 15-year-olds

mRNA (Pfizer or Moderna) COVID-19 Vaccine Preference

- It is preferred that persons aged 18 years receive an mRNA COVID-19 vaccine (Pfizer or Moderna) over the Janssen COVID-19 Vaccine for primary and booster vaccination
- Persons aged 18 years and older who received Janssen primary vaccination should preferably receive an mRNA vaccine dose at least 2 months (8 weeks) later
- Offering the Janssen COVID-19 Vaccine is preferable to not providing any COVID-19 vaccine
- Janssen COVID-19 vaccine may be considered in some situations
- **Janssen COVID-19 Vaccine is contraindicated in persons with a history of thrombosis with thrombocytopenia syndrome (TTS) following receipt of the Janssen COVID-19 Vaccine or any other adenovirus vector-based COVID-19 vaccines (e.g., AstraZeneca's COVID-19 Vaccine, which is not authorized or approved in the United States)**
- Persons should be counseled that mRNA vaccines are preferred over the Janssen COVID-19 Vaccine and that there is a risk of TTS following receipt of Janssen vaccine

Shortened interval for Pfizer & Moderna to 5 months

MDHHS Press Release [\(1-6-22\)](#)


- The interval for booster vaccination should follow the interval recommended for the primary series
- Persons aged 18 years and older who received Janssen primary vaccination should preferably receive an mRNA vaccine booster dose at least 2 months (8 weeks) later
- Persons aged 12 years and older who received an mRNA COVID-19 vaccine primary series (including those who received two doses of different mRNA vaccine products) should receive a single booster dose at least 5 months after the last dose administered
- Moderately or severely immunocompromised people ages 12 years and older who received an mRNA COVID-19 vaccine primary series, and an additional primary mRNA vaccine dose **should receive** a single COVID-19 booster dose (preferably with an mRNA COVID-19 vaccine) at least 5 months after completing their additional primary dose
- For people ages 12–17 years, only Pfizer-BioNTech COVID-19 Vaccine can be used for booster vaccination at this time

Expanded Booster Dose Rec. for 12 through 15 Year Old's

MDHHS Press Release [\(1-6-22\)](#)

- All people 12 years and older **should receive** a booster dose of COVID-19 vaccine, even if they were age 11 years or younger at the time of the primary series
- In people ages 12 through 17 years, only Pfizer-BioNTech COVID-19 vaccine can be used for the booster dose
- Currently, CDC does not recommend a booster dose in children ages 5 through 11 years, regardless of other characteristics or medical conditions


Additional (3rd) Dose Update



Additional (3rd) Dose for Immunocompromised Now Includes 5-11 Year Old's

- [Moderately or severely immunocompromised](#) people 5 years of age and older who received an initial mRNA COVID-19 vaccine primary series **should receive** an additional primary dose of the same mRNA COVID-19 vaccine as was administered for the primary series at least 28 days after completion of the initial 2-dose series.
- An additional dose should be administered as follows:
 - Pfizer-BioNTech:
 - 30µg in a volume of 0.3mL (purple or gray cap formulation) for people ages 12 years and older
 - 10µg in a volume of 0.2mL (orange cap formulation) for people ages 5 through 11 years
 - Moderna:
 - 100µg in a volume of 0.5mL for people ages 18 years and older

**Fully Vaccinated vs.
Up to Date**



Defining Fully Vaccinated and Up to Date

- A person is considered fully vaccinated with vaccines against COVID-19 infection 2 or more weeks after receipt of the second dose in a 2-dose mRNA vaccine series (Pfizer or Moderna) or 2 or more weeks after receipt of a single dose of the Janssen (Johnson and Johnson) COVID-19 Vaccine
- CDC recommends that people **remain up to date** with their vaccines, which includes additional doses for individuals who are immunocompromised or booster doses at regular time points
 - Currently there is no COVID-19 vaccine available, authorized, or recommended for use in persons birth through 4 years of age

[Stay Up to Date with Your Vaccines | CDC](#)



Your Health

Vaccines

Cases & Data

Work & School

Healthcare Workers

Health Depts

Science

More

Vaccines

Your Vaccination +

Types of Vaccines Available +

Possible Side Effects

Stay Up to Date with Vaccines -

Possibility of COVID-19 Illness after Vaccination

Safety & Monitoring +

COVID-19 Vaccines are Effective +

Myths & Facts +

Frequently Asked Questions +

About COVID-19 Vaccines +

Communication Resources +

Archive

Stay Up to Date with Your Vaccines

Updated Jan. 16, 2022

Languages ▾

Print

Get Vaccinated and Stay Up to Date

Up to date means a person has received all recommended doses and is eligible.

Fully vaccinated means a person has received their primary series.

COVID-19 Vaccines

[COVID-19 vaccines](#) available in the United States are effective at preventing hospitalization, and even dying. As with vaccines for other diseases, the CDC recommends that everyone 5 years and older get their vaccine when eligible.

When Are You Up to Date?

You are up to date with your COVID-19 vaccines when you have received all recommended doses. Recommendations will be different depending on your age and health status.


Many people who are [immunocompromised](#) may need additional doses.

Note that booster shots are not recommended for everyone at this time.

Pfizer-BioNTech ⁽¹⁾	Moderna ⁽¹⁾	Johnson & Johnson's Janssen ^(1,2)
Ages Recommended 5+ years old	Ages Recommended 18+ years old	Ages Recommended 18+ years old
Primary Series 2 doses ^(3,4) Given 3 weeks (21 days) apart ⁽⁵⁾	Primary Series 2 doses ⁽³⁾ Given 4 weeks (28 days) apart ⁽⁵⁾	Primary Series 1 dose
Fully Vaccinated 2 weeks after final dose in primary series	Fully Vaccinated 2 weeks after final dose in primary series	Fully Vaccinated 2 weeks after 1st dose
Booster Dose Everyone ages 12+ should get a booster dose at least 5 months after the last dose in their primary series. <ul style="list-style-type: none"> Teens 12–17 should only get a Pfizer-BioNTech COVID-19 Vaccine booster Everyone 18+ should get a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) 	Booster Dose Everyone ages 18+ should get a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) at least 5 months after the last dose in their primary series.	Booster Dose Everyone ages 18+ should get a booster dose of either Pfizer-BioNTech or Moderna (mRNA COVID-19 vaccines) at least 2 months after the first dose of J&J/Janssen COVID-19 Vaccine. You may get J&J/Janssen in some situations .
When Boosted A person is considered "boosted" and up to date right after getting their booster dose.	When Boosted A person is considered "boosted" and up to date right after getting their booster dose.	When Boosted A person is considered "boosted" and up to date right after getting their booster dose.

[Stay Up to Date with Your Vaccines](#) | CDC

EUA Fact Sheets Updated



CONTENT-SPECIFIC COVID-19 RESOURCES

Webinars

- **Upcoming Noontime Knowledge: January 27, 2022**

Education Corner - Email Archive

Enrollment

Redistribution

Vaccine Billing and Vaccine Code Sets

Product-Specific Information, EUAs & EUIs

Pfizer

Moderna

Janssen (Johnson & Johnson)

EUA Fact Sheets

- EUA Fact Sheet for Healthcare Professionals
 - **5 Through 11 Years of Age, Orange Cap (must dilute) - UPDATED 1/3/22**
 - **12 Years of Age and Older, Purple Cap (must dilute) - UPDATED 1/3/22**
 - **12 Years of Age and Older, Gray Cap (do not dilute) - UPDATED 1/3/22**
- EUA Fact Sheet for Recipients
 - **5 Through 11 years of Age - UPDATED 1/3/22**
 - Spanish - **UPDATED 10/29/21**
 - **12 Years of Age and Older - UPDATED 1/3/22**
 - Spanish - **UPDATED 10/29/21**
 - Important: Print and provide the above EUA Fact Sheet to each COVID-19 vaccine recipient/caregiver in Michigan.
 - This version includes the information statement about the MCIR (as indicated in Michigan VISs). Per state law, patients/parents must be informed about MCIR.
- **Translations 12 Years of Age and Older - UPDATED 10/20/21**
 - Chinese Simplified - **UPDATED 10/20/21**
 - Haitian - Creole - **UPDATED 10/20/21**
 - Hmong - **UPDATED 10/20/21**
 - Korean - **UPDATED 10/20/21**
 - Spanish - **UPDATED 10/20/21**
 - Tagalog - **UPDATED 10/20/21**
 - Vietnamese - **UPDATED 10/20/21**

ENGLISH

FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING VACCINE (VACCINATION PROVIDERS)

EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19)

**FOR 12 YEARS OF AGE AND OLDER
DO NOT DILUTE**

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Pfizer-BioNTech COVID-19 Vaccine, for active immunization to prevent COVID-19 in individuals 5 years of age and older.

There are 2 formulations of Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals 12 years of age and older:

The formulation supplied in a multiple dose vial with a gray cap and label with a gray border IS NOT DILUTED PRIOR TO USE.

The formulation supplied in a multiple dose vial with a purple cap MUST BE DILUTED PRIOR TO USE.

This Fact Sheet pertains only to Pfizer-BioNTech COVID-19 Vaccine supplied in a multiple dose vial with a gray cap and a label with a gray border which is authorized for use in individuals 12 years of age and older and MUST NOT BE DILUTED PRIOR TO USE.

Pfizer-BioNTech COVID-19 Vaccine supplied in a multiple dose vial with a gray cap and a label with a gray border is authorized for use to provide:


- a 2-dose primary series to individuals 12 years of age and older;
- a third primary series dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise;
- a single booster dose to individuals 12 years of age and older who have completed a primary series with Pfizer-BioNTech COVID-19 Vaccine or COMIRNATY (COVID-19 Vaccine, mRNA); and
- a single booster dose to individuals 18 years of age and older who have completed primary vaccination with a different authorized COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

COMIRNATY (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech that is indicated for active immunization

Updated EUA Fact Sheets

www.michigan.gov/covidvaccineprovider

Clinical Considerations




Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Reference Materials

[Summary Document for Interim Clinical Considerations](#) 

[COVID-19 Vaccine Administration Error Revaccination Guidance](#) 

[COVID-19 Vaccine Administration Error Revaccination Guidance – Poster](#) 

Get Email Updates

To receive email updates about this page, enter your email address:

[What's this?](#)

Submit

Summary of recent changes (last updated January 6, 2022):

- Updated guidance for use of Pfizer-BioNTech COVID-19 Vaccine as a booster in people ages 12–17 years
- Updated guidance for administration of a COVID-19 vaccine booster dose at least 5 months after completion of an mRNA vaccine (Pfizer-BioNTech or Moderna) primary series
- Updated guidance for use of an additional primary dose for moderately or severely immunocompromised people ages 5–11 years who received a Pfizer-BioNTech vaccine primary series
- Updated recommendations for people who received COVID-19 vaccines outside the United States that are not FDA-authorized or approved

Key points

- COVID-19 vaccines currently approved or authorized by FDA [are effective](#) in preventing serious outcomes of COVID-19, including severe disease, hospitalization, and death.
- COVID-19 primary series vaccination is recommended for everyone ages 5 years and older in the United States for the prevention of coronavirus disease 2019 (COVID-19).
- In most situations, Pfizer-BioNTech or Moderna COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for primary and booster vaccination.
- An additional primary mRNA COVID-19 vaccine dose is recommended at least 28 days later for moderately or severely immunocompromised people ages 5 years and older who received a 2-dose mRNA vaccine primary series.
- A booster dose of COVID-19 vaccine is recommended for everyone ages 12 years and older (Pfizer-BioNTech for ages 12–17; an mRNA vaccine preferred for ages 18 years and older):
 - At least 5 months after completion of an mRNA vaccine (Pfizer-BioNTech or Moderna) primary series.
 - At least 2 months after completion of a Janssen COVID-19 Vaccine primary dose.
- Efforts to maximize the proportion of people in the United States who are [up to date](#) with their COVID-19 vaccines remain critical to ending the COVID-19 pandemic.
- These clinical considerations provide additional information to healthcare professionals and public health officials on use of COVID-19 vaccines.

On This Page

Purpose

[Vaccination of children and adolescents](#)

[COVID-19 vaccines](#)

[Patient counseling](#)

[Groups recommended for vaccination](#)

[Considerations for mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna](#)

[Primary series](#)

[Considerations for Janssen COVID-19 Vaccine](#)

[Additional primary dose](#)

[Contraindications and precautions](#)

[Booster dose](#)

[Reporting of vaccine adverse events](#)

[Interchangeability of COVID-19 vaccine products](#)

[Laboratory testing](#)

[Coadministration of COVID-19 vaccines with other vaccines](#)

[Appendix A. Vaccine administration errors and deviations](#)

[People who received COVID-19 vaccine outside the United States](#)

[Appendix B: Triage of people with a history of allergies or allergic reactions](#)

[People who received COVID-19 vaccine as part of a clinical trial](#)

[Appendix C: Ingredients included in COVID-19 vaccines](#)

[COVID-19 vaccination and SARS-CoV-2 infection](#)

[Appendix D: Potential characteristics of allergic reactions, vasovagal reactions, and vaccine side effects following COVID-19 vaccination](#)

[Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks](#)

[References](#)

[Considerations for COVID-19 vaccination in moderately or severely immunocompromised people](#)


[Previous Updates](#)

[Considerations involving pregnancy, lactation, and fertility](#)

CDC Interim Clinical Considerations for Use of COVID-19 Vaccines




<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

Pfizer BioNTech's Gray Cap



Pfizer BioNTech's Gray Cap

- Pfizer 1170 (purple cap) no longer available for ordering
- Pfizer Tris/Gray Cap was available beginning 12/27
 - Please use up on-hand doses of Pfizer 1170/purple cap prior to using gray cap to avoid administration errors
 - Be sure to select the correct vaccine when entering administration data into MCIR (gray cap vs. purple cap)

Description	Dilute Before Use	Do Not Dilute	Dilute Before Use
Age Group	12 years and older ^{1,2}	12 years and older ³	5 through 11 years ⁴ ("Age 5y to <12y" on vial label)
Vial Cap Color	Purple 	Gray 	Orange 
Dose	30 mcg	30 mcg	10 mcg
Dose Volume	0.3 mL	0.3 mL	0.2 mL
Amount of Diluent Needed per Vial*	1.8 mL	NO DILUTION	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)
Storage Conditions			
Ultra-Low-Temperature (ULT) Freezer [-90°C to -60°C (-130°F to -76°F)]	9 months [†]	9 months [†]	9 months [†]
Freezer [-25°C to -15°C (-13°F to 5°F)]	2 weeks	DO NOT STORE	DO NOT STORE
Refrigerator [2°C to 8°C (35°F to 46°F)]	1 month	10 weeks	10 weeks
Room Temperature [8°C to 25°C (46°F to 77°F)]	2 hours prior to dilution (including any thaw time)	12 hours prior to first puncture (including any thaw time)	12 hours prior to dilution (including any thaw time)
After First Puncture [2°C to 25°C (35°F to 77°F)]	Discard after 6 hours	Discard after 12 hours	Discard after 12 hours




Expiration Guidance



Expiry information for **Ages 5 through 11**
DILUTE BEFORE USE Orange Cap presentation
and **Ages 12 years and older DO NOT DILUTE**
Gray Cap presentation

Printed Manufacturing Date	9-Month Expiry Date
06/2021	28-Feb-2022
07/2021	31-Mar-2022
08/2021	30-Apr-2022
09/2021	31-May-2022
10/2021	30-Jun-2022
11/2021	31-Jul-2022
12/2021	31-Aug-2022
01/2022	30-Sep-2022
02/2022	31-Oct-2022

- Vials can be stored up to 9 months in an Ultra Cold Freezer -90°C to -60°C (-130°F to -76°F)
- Once the vials are thawed and moved to the refrigerator 2°C to 8°C (35°F to 46°F), the vials may be stored for up to 10 weeks
 - The carton should be updated to reflect the 10-week expiration date
- **Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons**




Pfizer Expiration Date in MCIR

- A glitch within Pfizer's order management system affected expiration dates (showing expiration as 6 months after manufacture rather than the updated 9 months) within CDC's data feed in VTrckS
- Due to this glitch, Pfizer Tris-Sucrose Adolescent/Adult vaccine (Gray Cap) and Pfizer Pediatric (Orange Cap) vaccines in MCIR inventories may display an expiration date of 6 months from the date of manufacture listed on the vial. The correct expiration date is 9 months from the date of manufacture, provided the vaccine has been kept in ultracold storage
 - The glitch affected the Pfizer Gray Cap and Orange Cap vaccines in MCIR through January 18, 2022
- **This extension applies to frozen Ultra Low Temperature (ULT) inventories only**
- **Please review your Pfizer vaccine in inventory and update the expiration date manually if necessary**


[CorrectExpirationDateintheMCIR-6.9.2021.pdf](#)

Moderna Label Changes




Moderna Label Changes

- FDA recently approved updates to the label for the Moderna COVID-19 vaccine
- Distribution of the Moderna vials with the updated labels (see new label below) began during the week of January 13, 2022
- What has changed on the label of the Moderna COVID-19 vaccine:
 - The label has been updated to indicate a volume of 5.5mL
 - Doses for primary series and booster shots are now listed on the label
 - Important reminder not to exceed a maximum of 20 punctures per vial
- What remains the same for the Moderna COVID-19 vaccine
 - Formulation
 - NDC [80777-273-99]
 - Physical vial size
 - Number of reportable doses
 - Dose volumes
 - Reporting requirements
 - Wastage should continue to be reported based on 10 doses per vial
 - Each vial can ONLY be punctured up to 20 times
 - Once the vial has reached the 20-puncture limit, the vial should be discarded even if there is vaccine remaining in the vial



Fact Check




Yes. Moderately or severely immunocompromised people may not mount a protective immune response after initial vaccination and, furthermore, their protection by primary vaccination may wane over time making them susceptible to severe SARS-CoV-2 infection. ACIP and CDC have made age-specific recommendations for an additional primary dose and a booster dose for this population.

Is it possible that some individuals will get 4 doses of COVID-19 vaccine?

The 5 through 11 years of age formulation (orange cap) has a 10ug concentration of mRNA and the 12 years of age and older formulation (purple cap) has a 30ug concentration. Can I use 1/3 of the purple cap dose to vaccinate a child that is 5 through 11 years of age?

No. You cannot use the 12 years of age and older formulation (purple cap) to vaccinate a child between 5 through 11 years of age, even if it is one third of the purple cap dose. Although it might appear that one third of the purple cap formulation (0.1 mL) would be equivalent to a 10ug concentration of mRNA per dose, the correct concentration of mRNA cannot be guaranteed in such a small volume of vaccine.

Resources



COVID-19 Vaccine Resource Guide

COVID-19 Vaccine	Pfizer ¹ :	Pfizer ² :	Pfizer ³ :	Moderna ⁴ (Note: Booster Dose Volume)*	J&J/ Janssen ⁵ Not Preferred ⁶ (mRNA vaccines are preferred for the primary and booster doses)
	Orange Cap	Purple Cap	Gray Cap DO NOT DILUTE		
Primary Series: Age Indication	5 through 11 years	12 years and older	12 years and older	18 years and older	18 years and older
Number of Doses	2 doses	2 doses	2 doses	2 doses	1 dose
Interval Between Doses	21 days	21 days	21 days	28 days	Not Applicable
Dose Volume	0.2mL	0.3mL	0.3mL	0.5mL	0.5mL

Please See Page 2 For Guidance Specific to Additional (3rd) Dose and Booster Dose

Preparation/dosage: (Discard diluent vial after one use, even if diluent remains)	1.3mL diluent/ 0.2mL dose	1.8mL diluent/ 0.3mL dose	DO NOT DILUTE/ 0.3mL dose	DO NOT DILUTE/ 0.5mL dose OR 0.25mL dose for booster only	DO NOT DILUTE/ 0.5mL dose
Storage Requirements: DO NOT REFREEZE VACCINE See below for temperature ranges [†]	Ultra-Cold Freezer: Until expiration date ¹	Ultra-Cold Freezer: expiry date on label + 3 months	Ultra-Cold Freezer: Until expiration date ³	DO NOT STORE IN ULTRA-COLD FREEZER	DO NOT STORE IN ULTRA-COLD FREEZER
	DO NOT STORE IN A STANDARD FREEZER	Freezer: 2 weeks	DO NOT STORE IN A STANDARD FREEZER	Standard Freezer: Until expiration date ⁷ (QR code)	DO NOT STORE IN A STANDARD FREEZER
	Refrigerator: 10 weeks	Refrigerator: 31 days	Refrigerator: 10 weeks	Refrigerator: 30 days	Refrigerator: Until expiration date ⁸ (QR code)
Thaw Time	30 minutes-4 hours	30 minutes-3 hours	30 minutes-6 hours	Refrigerator-2.5 -3 hours Room Temp-1 hour	DO NOT FREEZE
Room Temp Unpunctured	12 hours	2 hours	12 hours	24 hours	12 hours
Room Temp Punctured (Room temp in syringe)	12 hours	6 hours	12 hours	12 hours	2 hours

[†]Ultra-Cold Freezer: -90°C to -60°C (-130°F to -76°F) Standard Freezer: -25°C to -15°C (-13°F to 5°F) Refrigerator: 2°C to 8°C (35°F to 46°F)

Michigan Department of Health and Human Services

Revised: 1-13-22

MDHHS COVID-19 Resource Guide

www.Michigan.gov/COVIDvaccineprovider

Pfizer ² :	Pfizer ³ :	Moderna ⁴ (Note: Booster Dose Volume)*	J&J/ Janssen ⁵ Not Preferred ⁶ (mRNA vaccines are preferred for the primary and booster doses)
Purple Cap	Gray Cap DO NOT DILUTE		
12 years and older	12 years and older	18 years and older	No Recommendation
28 days	28 days	28 days	Not Applicable
0.3mL	0.3mL	0.5mL	Not Applicable
12 years and older with a complete Primary Series	12 years and older with a complete Primary Series	18 years and older with a complete Primary Series	18 years and older with a complete Primary Series (mRNA vaccines preferred) ⁶
5 months or greater	5 months or greater	5 months or greater	2 months or greater
0.3mL	0.3mL	0.25mL*	0.5mL
12 years and older with a 2-dose primary series and an additional dose	12 years and older with a 2-dose primary series and an additional dose	18 years and older with a 2-dose primary series and an additional dose	Not Applicable



NEW!

NEW

Revised: 1-13-22

Interactive COVID-19 Vaccine Conversations Module for Healthcare Professionals



Talking with Patients about COVID-19 Vaccination

Welcome to the Interactive COVID-19 Vaccine Conversation Module for Healthcare Professionals (HCPs). This tool has been developed by Centers for Disease Control and Prevention in partnership with the U.S. Department of Veteran Affairs.

Whether in your office, hospital, or through a telehealth visit, building confidence in COVID-19 vaccination among your patients is critical to setting expectations, ensuring vaccine uptake, and helping protect our communities.



Before beginning the interactive module, please review the following background information on the importance of vaccine confidence.

The Role of Healthcare Providers in Building Vaccine Confidence

5 COVID-19 Vaccine Conversations in Practice: Case Scenarios

Now that we have covered the basics of vaccine confidence and some tips on how to have better conversations with patients, let's explore some case scenarios that illustrate how these conversations might look in real healthcare settings.

NEW!


[COVID-19 Vaccine Conversations Tool for Healthcare Professionals | CDC](#)

CDC Resources on Building Vaccine Confidence

- [What Is Vaccine Confidence? | CDC](#)
- [COVID-19 Vaccine FAQs for Healthcare Professionals | CDC](#)
- [How to Address COVID-19 Vaccine Misinformation | CDC](#)
- [How to Tailor COVID-19 Vaccine Information to Your Specific Audience | CDC](#)

Updated COVID-19 Vaccine Web Resources

- [COVID-19 Vaccines for Long-term Care Residents](#)
- [Reporting COVID-19 Vaccinations in the United States](#)
- [COVID-19 Vaccine FAQs for Healthcare Professionals](#)
- [COVID-19 Vaccine Quick Reference Guide for Healthcare Professionals](#)
- [COVID-19 Vaccination Clinical & Professional Resources](#)
- [CDC COVID-19 Vaccination Program Provider Requirements and Support](#)
- [U.S. COVID-19 Vaccine Product Information](#)
- [Pfizer-BioNTech COVID-19 Vaccine \(Gray Cap\) Age 12 and Over](#)
- [Pfizer-BioNTech COVID-19 Vaccine \(Purple Cap\) Age 12 and Over](#)
- [Pfizer-BioNTech \(COMIRNATY\) COVID-19 Vaccine Questions](#)
- [The Federal Retail Pharmacy Program for COVID-19 Vaccination](#)



This webpage will house materials to support COVID-19 Vaccine Providers in successful implementation of the COVID-19 Vaccination Program. Be sure to "bookmark" this page and check back frequently for updates!

GENERAL COVID-19 VACCINE RESOURCES

COVID-19 Resource Guide -- Each Vaccine *1/13/22*

Clinical Guidance for Michigan Providers Regarding Additional Dose of an mRNA COVID-19 Vaccine

Increasing Access to Vaccine Opportunities: Recommendations for Health Care Providers - *Updated 6/18/21*

COVID-19 Vaccines During Hospital Stays and Medical Appointments - *Updated 6/14/21*

COVID-19 Vaccination Clinic Preparation Checklist & Resource Toolkit - *Updated 5/28/21*

ACIP Recommendations for COVID-19 Vaccine

Interim Clinical Considerations for COVID-19 Vaccine

CDC COVID-19 Vaccine Resources for Healthcare Professionals

- Vaccine administration, storage and handling, reporting, and patient education for each specific vaccine

COVID-19 Vaccine Training Module

- Self-paced module with certificate of completion (no CE)
- MDHHS strongly recommends that all COVID-19 Vaccine Providers complete this training.

CDC HCP Vaccine Administration Resource Library

CONTENT-SPECIFIC COVID-19 RESOURCES

Webinars

- *Upcoming Noontime Knowledge: January 27, 2022*

Education Corner - Email Archive

Enrollment

Redistribution

Vaccine Billing and Vaccine Code Sets

Product-Specific Information, EUAs & EUIs

MDHHS COVID-19 Provider Guidance and Education Website

www.michigan.gov/covidvaccineprovider

Thank You!

Next “Noontime
Knowledge” Update: TBD

Please watch your email for
an updated link and topic!

Questions Email:
checcimms@michigan.gov

www.michigan.gov/COVIDvaccineprovider

